University of South Florida - Health Byrd Alzheimer Institute
Welcome,         Profile    Billing    Logout  
 49 Trials 
99 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Newhouse, Paul A
NCT05231798: Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition

Recruiting
2
20
US
[18F]-FEOBV Radiotracer, [18F]-fluoroethoxybenzovesamicol
Vanderbilt University Medical Center, Vanderbilt Kennedy Center
Down Syndrome, Down Syndrome, Partial Trisomy 21, Alzheimer Disease
02/25
02/25
MIND, NCT02720445: Memory Improvement Through Nicotine Dosing () Study

Active, not recruiting
2
380
US
Nicotine Transdermal Patch, Placebo Patch
University of Southern California, National Institute on Aging (NIA), Vanderbilt University, Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment
09/25
09/25
2-HOBA, NCT06432166: 2-Hydroxybenzylamine () Study in Early Alzheimer's Patients

Not yet recruiting
1/2
48
US
2-hydroxybenzylamine acetate, 2-HOBA, Placebo
MTI Biotech Inc, Vanderbilt University Medical Center
Alzheimer Disease, Mild Cognitive Impairment
06/27
12/27
CHAMP, NCT04129060: Cholinergic Health After Menopause

Recruiting
1
120
US
Cholinergic antagonist
University of Vermont, Vanderbilt University Medical Center
Postmenopausal Symptoms, Aging, Alzheimer Disease
11/24
01/25
NCT04756232: Cholinergic Mechanisms of Attention in Aging

Recruiting
1
80
US
Mecamylamine Challenge, Placebo Comparator Challenge
Vanderbilt University Medical Center
Subjective Cognitive Decline
05/25
05/25
AMoCC-SCD, NCT06002477: Attentional Mechanisms in SCD

Not yet recruiting
1
80
US
Mecamylamine Challenge, Placebo Comparator Challenge
Vanderbilt University Medical Center
Subjective Cognitive Decline
06/28
06/28
NCT05283629: nCCR for Chemotherapy Related Cognitive Impairment Randomized Study

Recruiting
N/A
20
US
Neuroplasticity-based Computerized Cognitive Remediation, Education Control Condition
Vanderbilt University Medical Center, University of Utah
Chemo-brain, Chemotherapy-Related Cognitive Impairment
06/24
03/25
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
TRC-DS, NCT04165109: Trial-Ready Cohort-Down Syndrome

Recruiting
N/A
450
Europe, US
Flutafuranol, [18F]NAV4694, NAV4694, Pittsburgh Compound (PIB), [11C]-PIB, PIB, MK6240, [18F]MK-6240
University of Southern California, National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium, Alzheimer's Therapeutic Research Institute
Down Syndrome, Alzheimer Disease, Dementia
12/25
12/25
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27
Pomara, Nunzio
NCT05004987: Aβ Dynamics in LLMD

Recruiting
4
90
US
Escitalopram Oxalate, Lexapro, ESC, Placebo, PBO
NYU Langone Health, National Institute on Aging (NIA)
Alzheimer Disease, Major Depressive Disorder
04/26
06/26
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Enrolling by invitation
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
NCT04784416: Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

Recruiting
2
125
US
Active tPBM-2.0, Sham tPBM-2.0, 18F-MK-6240
NYU Langone Health, National Institutes of Health (NIH), Alzheimer's Association, LiteCure LLC
Mild Cognitive Impairment, Alzheimer Disease
10/25
01/26
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27
Nguyen, Trung
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
NRG-GY019, NCT04095364: Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recruiting
3
450
Europe, Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Imaging Technique, Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), imaging procedure, Imaging Procedures, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging, Letrozole, CGS 20267, Femara, Fempro, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
02/27
02/28
COBRA, NCT04068103: Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Active, not recruiting
2/3
1408
Canada, US
Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, citrovorum factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Patient Observation, Active Surveillance, deferred therapy, expectant management, observation, Watchful Waiting
NRG Oncology, National Cancer Institute (NCI)
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
06/23
04/27
NCT04905134: Low-Cost, Portable Flexible Nasopharyngoscope in Head & Neck Cancers in Low Resource Settings - Optimization Phase

Completed
N/A
53
US
Nasopharyngoscope
Duke University, National Institute of Dental and Craniofacial Research (NIDCR)
Head and Neck Cancer, Oral Cancer
09/23
09/23
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27
Grossman, Hillel
NCT02033941: Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)

Terminated
2
10
US
Meganatural-Az Grapeseed Extract, Grapeseed Polyphenolic Extract, Grapeseed Phenol Extract, GSPE, Placebo
Hillel Grossman, National Center for Complementary and Integrative Health (NCCIH)
Alzheimer's Disease
10/19
10/19
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27
Stern, Yaakov
NCT01222351: Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172

Completed
N/A
161
US
BAY 94-9172 (Florbetaben), Florbetaben, Bay 91-9172
New York State Psychiatric Institute, Bayer, National Institute on Aging (NIA)
Late Onset Alzheimer Disease
10/14
10/14
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
NCT01556230: Prospective Study of Clinically Nonfunctioning Pituitary Adenomas

Completed
N/A
292
US
Surgical intervention for CNFA, Radiotherapy for CNFA
Columbia University, National Institute of Neurological Disorders and Stroke (NINDS)
Pituitary Adenoma, Pituitary Tumor
06/24
06/24
NCT03372317: Tau PET in Imaging and Cognition: Healthy Adults From 55-90

Recruiting
N/A
105
US
18F-MK-6240, 6-[18F]Fluoro-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine
Yaakov Stern, National Institute on Aging (NIA)
Mild Cognitive Impairment, Aging
01/27
12/27
Lopez, Oscar
S-CitAD, NCT03108846: Escitalopram for Agitation in Alzheimer's Disease

Active, not recruiting
3
187
Canada, US
Escitalopram, Lexapro, Placebo, non-applicable
JHSPH Center for Clinical Trials, National Institute on Aging (NIA)
Dementia
04/24
05/25
ACE, NCT05741060: Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers

Active, not recruiting
2
372
US
S-equol, Equelle, Placebo
Akira Sekikawa, National Institute on Aging (NIA)
Arterial Stiffness, White Matter Lesions, Cognitive Decline
10/26
01/27
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
BHI, NCT04708613: University of Pittsburgh Brain Health Initiative

Recruiting
N/A
300
US
Cognitive/Neuropsychological Testing, Vestibular/Ocular-Motor Testing, Sleep Evaluation, MRI, High-Resolution, Health & Physical Exam, Physical Function, Blood Testing and Biomarker Analysis, Applanation Tonometry, Continuous arterial pressure, PET brain imaging, [C-11]6-OH-BTA-1, Pittsburgh Compound B, [F-18]AV-1451, [F-18]T807, LY3191748
David Okonkwo, MD, PhD, National Football League Scientific Advisory Board, Avid Radiopharmaceuticals, Inc., Harvard University
Traumatic Brain Injury
12/25
12/25
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27
Smith, Amanda
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated
3
1125
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
12/24
12/24
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
PACT, NCT03848312: Preventing Alzheimer's With Cognitive Training

Recruiting
3
7600
US
Cognitive Training, Computerized Cognitive Stimulation
University of South Florida, National Institute on Aging (NIA)
Age-related Cognitive Decline, Alzheimer's Disease and Related Dementias
01/26
01/26
REVERCE II, NCT04117945: Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Active, not recruiting
2
22
US
Cetuximab, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Irinotecan, Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, MoAb ABX-EGF, Monoclonal Antibody ABX-EGF, Vectibix, Regorafenib, BAY 73-4506, Stivarga
Academic and Community Cancer Research United, National Cancer Institute (NCI)
BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, NRAS Gene Mutation Negative, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
09/23
03/25
RAD 2003, NCT04743934: Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

Active, not recruiting
2
44
US
Flibanserin 100 MG, Placebo, Androgen deprivation therapy
Andrew McDonald, National Cancer Institute (NCI)
Prostate Adenocarcinoma
03/25
03/26
Spectra, NCT05393284: Phase 2 Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

Active, not recruiting
2
114
US
OPL-0401 Dose 1, Placebo
Valo Health, Inc.
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
08/24
08/24
MAGIC, NCT05681884: Safety and Efficacy of Faricimab in Patients With NPDR

Active, not recruiting
2
179
US
Faricimab
Greater Houston Retina Research, Genentech, Inc.
Non-Proliferative Diabetic Retinopathy
03/26
04/26
NCT05715346: LEV102 Topical Gel in Acquired Blepharoptosis

Completed
1/2
33
US
LEV102 1.0%, LEV102 2.0%, Vehicle
Levation Pharma, Ltd.
Acquired Blepharoptosis
06/23
06/23
NCT04796012: VITAS: Atezolizumab in Combination with Chemotherapy for Pediatric Relapsed/refractory Solid Tumors

Recruiting
1/2
23
US
Atezolizumab, Tecentriq, Vincristine, Vincristine Sulfate Injection, Oncovin, Vincasar PES, Vincrex, Irinotecan, Irinotecan Hydrochloride Injection, Campto, Temozolomide, Temozolomide Capsules, Temodar
University of Texas Southwestern Medical Center
Solid Tumor, Rhabdomyosarcoma
01/25
01/25
TRC-PAD, NCT04004767: Program: In-Clinic Trial-Ready Cohort

Completed
N/A
220
US
University of Southern California, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, Alzheimer's Clinical Trials Consortium, Brigham and Women's Hospital, Cleveland Clinic Lou Ruvo Center for Brain Health
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
04/24
04/24
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
i-GAIN, NCT05797896: Investigating Geographic Atrophy Insights () Natural History Study

Recruiting
N/A
250
Europe, US
Complement Therapeutics
Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration, Macular Atrophy, Retinal Degeneration, Eye Diseases
12/26
12/26
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27
Capote, Horacio
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease

Completed
3
804
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
10/24
10/24
SIGNAL-AD, NCT04381468: SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

Completed
1/2
50
US
Pepinemab, Placebo
Vaccinex Inc., Alzheimer's Drug Discovery Foundation, Alzheimer's Association
Alzheimer Disease
06/24
06/24
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Recruiting
N/A
6800
US
Vagus Nerve Stimulation (VNS), VNS
LivaNova
Treatment Resistant Depression
02/28
12/30
Portseinsson, Anton
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
Silbert, Lisa
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27
Masdeu, Joseph
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
MIND, NCT02720445: Memory Improvement Through Nicotine Dosing () Study

Active, not recruiting
2
380
US
Nicotine Transdermal Patch, Placebo Patch
University of Southern California, National Institute on Aging (NIA), Vanderbilt University, Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment
09/25
09/25
OPA, NCT03971487: Ocrelizumab for Psychosis by Autoimmunity

Recruiting
1/2
40
US
Psychosis and cognitive assessments, Physical and neuro-cognitive evaluations, Safety labs and electrocardiogram, Ocrelizumab infusion
The Methodist Hospital Research Institute, Genentech, Inc.
Schizo-Affective Type of Psychosis, Schizophrenia
06/25
10/25
Veri-T-001, NCT05184569: Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

Recruiting
1
64
US
Verdiperstat, BHV-3241
Peter Ljubenkov, MD, National Institutes of Health (NIH), Alzheimer's Association, National Institute on Aging (NIA)
Semantic Dementia
06/26
09/26
LEADS, NCT03507257: Longitudinal Early-onset Alzheimer's Disease Study Protocol

Recruiting
N/A
850
Europe, US, RoW
Flortaucipir, 18F-AV-1451 (also known as [F-18]T807 or LY3191748), Florbetaben, AV-45, Neuraceq, Fluorodeoxyglucose, FDG
Indiana University, Alzheimer's Therapeutic Research Institute, National Institute on Aging (NIA), Alzheimer's Association
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
05/25
05/25
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
NCT04363684: ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

Recruiting
N/A
2100
Canada, US
Mayo Clinic, University of California, San Francisco, National Institute on Aging (NIA), National Institute of Neurological Disorders and Stroke (NINDS)
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
06/25
06/25
Hsiung, Robin
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated
3
1125
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
12/24
12/24
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
DIAN-TU-002, NCT06647498: A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Recruiting
2/3
280
Europe, Canada, US, RoW
Remternetug, LY3372993, Matching Placebo (Remternetug)
Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA), GHR Foundation, Private Donors
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
03/34
08/34
DIAN-TU, NCT05269394: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Active, not recruiting
2/3
197
Europe, Canada, Japan, US, RoW
E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Alzheimer's Association, National Institute on Aging (NIA), Accelerating Medicines Partnership (AMP), Eisai Inc.
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
DIAN-TU, NCT01760005 / 2013-000307-17: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol -001

Checkmark From DIAN-TU trial
Feb 2020 - Feb 2020: From DIAN-TU trial
Checkmark Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Feb 2020 - Feb 2020: Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Checkmark DIAN TU: N=210
More
Recruiting
2/3
490
Europe, Canada, Japan, US, RoW
Gantenerumab, RO4909832, Solanezumab, LY2062430, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), Avid Radiopharmaceuticals, Accelerating Medicines Partnership (AMP), Eisai Inc., Janssen, LP
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
DIAN-TU, NCT05552157: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Recruiting
2/3
280
Europe, Canada, US, RoW
Remternetug (SC), Matching Placebo (Remternetug)
Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA)
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
03/34
08/34
SARTAN-AD, NCT02085265: Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients

Recruiting
2
150
Canada
Perindopril, Coversyl, Telmisartan, Micardis
Sunnybrook Health Sciences Centre, Alzheimer's Drug Discovery Foundation, Weston Brain Institute
Alzheimer's Disease
09/23
09/23
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
COMPASS-ND, NCT03402919: Comprehensive Assessment of Neurodegeneration and Dementia

Recruiting
N/A
2300
Canada
McGill University, Canadian Institutes of Health Research (CIHR), Alzheimer Society of Canada, Sanofi, New Brunswick Health Research Foundation, Saskatchewan Health Research Foundation, Women's Brain Health Initiative, Michael Smith Foundation for Health Research, Alzheimer's Research UK, Alberta Prion Research Institute, Nova Scotia Health Research Foundation, Eli Lilly and Company, Canadian Nurses Foundation (CNF), Ontario Brain Institute, Consortium pour l'Identification precoce du Maladie Alzheimer du Quebec, Pfizer, Canadian Consortium on Neurodegeneration in Aging
Dementia
09/23
09/23
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
MITNEC C6, NCT02330510: Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease

Completed
N/A
80
Canada
Dr. Sandra E Black
Alzheimer's Disease, Small Vessel Disease White Matter Hyperintensities Subtype, Vascular Cognitive Impairment
12/24
12/24
Marshall, Gad
NCT06489548: Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease

Not yet recruiting
2
16
US
Foralumab TZLS-401 50 µg, Foralumab TZLS-401 100 µg
Brigham and Women's Hospital, Tiziana Life Sciences LTD
Dementia, Alzheimers Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
06/26
12/26
TRC-PAD, NCT04004767: Program: In-Clinic Trial-Ready Cohort

Completed
N/A
220
US
University of Southern California, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, Alzheimer's Clinical Trials Consortium, Brigham and Women's Hospital, Cleveland Clinic Lou Ruvo Center for Brain Health
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
04/24
04/24
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27
Sadowski, Martin
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
NEUP11-7, NCT05267535: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Active, not recruiting
2/3
225
Canada, US
Piromelatine 20 mg, Neu-P11, Placebo
Neurim Pharmaceuticals Ltd., Syneos Health
Alzheimer's Disease
06/25
06/25
NCT04784416: Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

Recruiting
2
125
US
Active tPBM-2.0, Sham tPBM-2.0, 18F-MK-6240
NYU Langone Health, National Institutes of Health (NIH), Alzheimer's Association, LiteCure LLC
Mild Cognitive Impairment, Alzheimer Disease
10/25
01/26
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Recruiting
2
282
Europe, Canada, US, RoW
GSK4527226, Placebo
GlaxoSmithKline, Alector Inc.
Alzheimer's Disease
12/26
02/29
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
Liss, Jonathan
TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting
3
800
Europe, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
05/24
05/25
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Enrolling by invitation
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated
3
1125
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
12/24
12/24
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting
3
1667
Japan, US
Remternetug (IV), LY3372993, Remternetug (SC), Placebo
Eli Lilly and Company
Alzheimer's Disease
06/24
03/26
NCT06677203: Study of ASN51 in Adults With Early Alzheimer's Disease

Recruiting
2
78
US
ASN51, Placebo
Asceneuron S.A.
Alzheimer Disease
09/26
09/26
TRC-PAD, NCT04004767: Program: In-Clinic Trial-Ready Cohort

Completed
N/A
220
US
University of Southern California, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, Alzheimer's Clinical Trials Consortium, Brigham and Women's Hospital, Cleveland Clinic Lou Ruvo Center for Brain Health
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
04/24
04/24
Wint, Dylan
TRC-PAD, NCT04004767: Program: In-Clinic Trial-Ready Cohort

Completed
N/A
220
US
University of Southern California, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, Alzheimer's Clinical Trials Consortium, Brigham and Women's Hospital, Cleveland Clinic Lou Ruvo Center for Brain Health
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
04/24
04/24
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
NCT04363684: ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

Recruiting
N/A
2100
Canada, US
Mayo Clinic, University of California, San Francisco, National Institute on Aging (NIA), National Institute of Neurological Disorders and Stroke (NINDS)
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
06/25
06/25
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27
Celmins, Dzintra
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated
3
1125
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
12/24
12/24
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27
Duffy, Charles
START, NCT05531656: A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Recruiting
2
540
US
CT1812, Study Drug Active, Placebo, Matching Placebo
Cognition Therapeutics, National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium
Early Alzheimer's Disease
04/27
04/27
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27

Download Options